Unilabs, a leading diagnostic provider in Europe, has implemented SOPHiA GENETICS' AI technology for HRD testing in solid tumors across its network in Switzerland. HRD, a common alteration in ovarian cancer, affects approximately half of newly diagnosed patients, making it a important factor in treatment planning. SOPHiA GENETICS' SOPHiA DDM™ Platform uses AI and machine learning to analyze NGS data quickly and accurately, enabling precise diagnostics and treatment guidance. The partnership between SOPHiA GENETICS and Unilabs aims to enhance precision medicine by providing cutting-edge testing and analysis services to patients in Europe. The implementation of the SOPHiA DDM™ Platform will support Unilabs in delivering fast and reliable testing results to patients, furthering the use of precision medicine in cancer care.